From Name:
From Email:
To Name:
To Email:

Optional Message:


Survival increased with first-line abiraterone-ADT combination for hormone-naïve prostate cancer

from Oncology Nurse Advisor

Adding abiraterone to androgen-deprivation therapy (ADT) as first-line treatment for advanced or high-risk prostate cancer (PCa) improves survival and delays disease progression compared with ADT alone, according to the findings of separate studies presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting and published concurrently in the New England Journal of Medicine. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063